Longterm renal outcome after 10 years enzyme replacement therapy with agalsidase A in Fabry male patients

被引：0
|
作者：
Karabul, Nesrin [1 ]
Arash, Laila [1 ]
Waechter, Maike [1 ]
Beck, Michael [1 ]
Kampmann, Christof [1 ]
Mengel, Eugen [1 ]
机构：
[1] Villa Metabol, Mainz, Germany
来源：
MOLECULAR GENETICS AND METABOLISM | 2014年 / 111卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2013.12.130
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
118
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [1] Fabry disease and enzyme replacement therapy: 10 years of experience with agalsidase beta
    Politei, Juan
    Schenone, Andrea
    Cabrera, Gustavo
    Amartino, Heman
    Szlago, Marina
    MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S87 - S87
  • [2] Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age
    Parini, Rossella
    Pintos-Morell, Guillem
    Hennermann, Julia B.
    Hsu, Ting-Rong
    Karabul, Nesrin
    Kalampoki, Vasiliki
    Gurevich, Andrey
    Ramaswami, Uma
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 2149 - 2158
  • [3] Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
    Germain, Dominique P.
    Charrow, Joel
    Desnick, Robert J.
    Guffon, Nathalie
    Kempf, Judy
    Lachmann, Robin H.
    Lemay, Roberta
    Linthorst, Gabor E.
    Packman, Seymour
    Scott, C. Ronald
    Waldek, Stephen
    Warnock, David G.
    Weinreb, Neal J.
    Wilcox, William R.
    JOURNAL OF MEDICAL GENETICS, 2015, 52 (05) : 353 - 358
  • [4] Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment
    Kampmann, Christoph
    Perrin, Amandine
    Beck, Michael
    ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [5] Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
    Christoph Kampmann
    Amandine Perrin
    Michael Beck
    Orphanet Journal of Rare Diseases, 10
  • [6] UNEVENTFUL PREGNANCY OUTCOME AFTER ENZYME REPLACEMENT THERAPY WITH AGALSIDASE BETA IN A PATIENT HETEROZYGOUS FOR FABRY DISEASE
    Germain, D. P.
    Tran, T. -C.
    Richalet, B.
    Benistan, K.
    CLINICAL THERAPEUTICS, 2009, 31 : S43 - S43
  • [7] LONG-TERM OUTCOME OF AGALSIDASE BETA THERAPY IN 10 ADULT MALE PATIENTS WITH FABRY DISEASE AND RENAL ALLOGRAFT
    Tran, T. -C.
    Benistan, K.
    Froissart, M.
    Germain, D. P.
    CLINICAL THERAPEUTICS, 2009, 31 : S39 - S40
  • [8] Enzyme replacement therapy with agalsidase alfa (replagal) stabilizes renal function in male patients with Fabry disease: Results of an integrated analysis
    West, Michael
    Schiffmann, Raphael
    Mehta, Atul
    Amato, David
    Nair, Nitin
    Zahrieh, David
    Huertas, Pedro
    MOLECULAR GENETICS AND METABOLISM, 2011, 102 (03) : 320 - 320
  • [9] Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta
    Mehta, Atul
    Beck, Michael
    Kampmann, Christoph
    Frustaci, Andrea
    Germain, Dominique P.
    Pastores, Gregory M.
    Sunder-Plassmann, Gere
    MOLECULAR GENETICS AND METABOLISM, 2008, 95 (1-2) : 114 - 115
  • [10] Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
    Christoph Kampmann
    Amandine Perrin
    Michael Beck
    Orphanet Journal of Rare Diseases, 11
12345